NYSE · GKOS
Glaukos Corporation
$242.48+$61.05 (+33.65%)
Glaukos Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.51% below the high.
Loading market information…
NYSE · BLCO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 4.49% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Bausch + Lomb Corporation’s next earnings report is currently expected on Feb 17, 2027, with estimated earnings per share of $0.33. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Bausch + Lomb Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Jul 30, 2025 | $0.07+16.67% vs estimate | $1.28B+0.31% vs estimate |
|---|
| Q1 2025 | Apr 30, 2025 | -$0.07-333.33% vs estimate | $1.13B-9.58% vs estimate |
|---|
| Q4 2024 | Feb 19, 2025 | $0.25+4.17% vs estimate | $1.28B+11.23% vs estimate |
|---|
THE ANALYST VIEW
17 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 6 contributors · Median target $22.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$242.48+$61.05 (+33.65%)
Glaukos Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.51% below the high.
$62.61+$1.15 (+1.87%)
Vaxcyte, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.01% below the high.
$58.08+$0.68 (+1.18%)
TG Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.06% below the high.
$60.49+$0.28 (+0.47%)
Arrowhead Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.65% below the high.
$30.79+$0.31 (+1.02%)
Oscar Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.05% below the high.
$115.07+$0.02 (+0.02%)
Arcellx, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.05% below the high.
$141.39+$2.41 (+1.73%)
Teleflex Incorporated’s quoted price sits in the upper half of its reported 52-week range, 2.49% below the high.
$93.39+$1.18 (+1.28%)
Merit Medical Systems, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.66% below the high.
